7.1LGSep 21, 2025
Training the next generation of physicians for artificial intelligence-assisted clinical neuroradiology: ASNR MICCAI Brain Tumor Segmentation (BraTS) 2025 Lighthouse Challenge education platformRaisa Amiruddin, Nikolay Y. Yordanov, Nazanin Maleki et al.
High-quality reference standard image data creation by neuroradiology experts for automated clinical tools can be a powerful tool for neuroradiology & artificial intelligence education. We developed a multimodal educational approach for students and trainees during the MICCAI Brain Tumor Segmentation Lighthouse Challenge 2025, a landmark initiative to develop accurate brain tumor segmentation algorithms. Fifty-six medical students & radiology trainees volunteered to annotate brain tumor MR images for the BraTS challenges of 2023 & 2024, guided by faculty-led didactics on neuropathology MRI. Among the 56 annotators, 14 select volunteers were then paired with neuroradiology faculty for guided one-on-one annotation sessions for BraTS 2025. Lectures on neuroanatomy, pathology & AI, journal clubs & data scientist-led workshops were organized online. Annotators & audience members completed surveys on their perceived knowledge before & after annotations & lectures respectively. Fourteen coordinators, each paired with a neuroradiologist, completed the data annotation process, averaging 1322.9+/-760.7 hours per dataset per pair and 1200 segmentations in total. On a scale of 1-10, annotation coordinators reported significant increase in familiarity with image segmentation software pre- and post-annotation, moving from initial average of 6+/-2.9 to final average of 8.9+/-1.1, and significant increase in familiarity with brain tumor features pre- and post-annotation, moving from initial average of 6.2+/-2.4 to final average of 8.1+/-1.2. We demonstrate an innovative offering for providing neuroradiology & AI education through an image segmentation challenge to enhance understanding of algorithm development, reinforce the concept of data reference standard, and diversify opportunities for AI-driven image analysis among future physicians.
1.2QMJun 16, 2020
Can tumor location on pre-treatment MRI predict likelihood of pseudo-progression versus tumor recurrence in Glioblastoma? A feasibility studyMarwa Ismail, Virginia Hill, Volodymyr Statsevych et al.
A significant challenge in Glioblastoma (GBM) management is identifying pseudo-progression (PsP), a benign radiation-induced effect, from tumor recurrence, on routine imaging following conventional treatment. Previous studies have linked tumor lobar presence and laterality to GBM outcomes, suggesting that disease etiology and progression in GBM may be impacted by tumor location. Hence, in this feasibility study, we seek to investigate the following question: Can tumor location on treatment-naïve MRI provide early cues regarding likelihood of a patient developing pseudo-progression versus tumor recurrence? In this study, 74 pre-treatment Glioblastoma MRI scans with PsP (33) and tumor recurrence (41) were analyzed. First, enhancing lesion on Gd-T1w MRI and peri-lesional hyperintensities on T2w/FLAIR were segmented by experts and then registered to a brain atlas. Using patients from the two phenotypes, we construct two atlases by quantifying frequency of occurrence of enhancing lesion and peri-lesion hyperintensities, by averaging voxel intensities across the population. Analysis of differential involvement was then performed to compute voxel-wise significant differences (p-value<0.05) across the atlases. Statistically significant clusters were finally mapped to a structural atlas to provide anatomic localization of their location. Our results demonstrate that patients with tumor recurrence showed prominence of their initial tumor in the parietal lobe, while patients with PsP showed a multi-focal distribution of the initial tumor in the frontal and temporal lobes, insula, and putamen. These preliminary results suggest that lateralization of pre-treatment lesions towards certain anatomical areas of the brain may allow to provide early cues regarding assessing likelihood of occurrence of pseudo-progression from tumor recurrence on MRI scans.